Lyka Labs Ltd Q2 FY26 – From Pregabalin Patents to Painful Profits: The Curious Case of the ₹305 Cr Pharma Underdog

1. At a Glance

Lyka Labs Ltd — the 49-year-old pharmaceutical veteran that manufactures everything from lyophilized injections to dermatological creams — has just delivered a Q2 FY26 that can be best described as “dermatologically tested for heartbreak.” With a market cap of ₹305 crore and a stock price of ₹85.2, Lyka looks less like a lab and more like a rollercoaster ride through the Indian pharma trenches.

Despite being backed by industry heavyweight Ipca Laboratories (holding a solid 40.98% stake), Lyka’s quarterly numbers tell a story of wild mood swings — Q2 FY26 revenue of ₹36.66 crore, but a net loss of ₹3.22 crore. Compare that to the previous quarter’s ₹0.99 crore profit, and you’ll see why investors are scratching their heads faster than someone trying Lyka’s new cosmeceutical cream sample.

Sales dropped 10.9% QoQ, profit nosedived 260%, and the stock still trades at a lofty P/E of 150 — which is like paying luxury prices for generic paracetamol. But hey, at least their OPM (Operating Profit Margin) held some dignity at 7.6%.

2. Introduction

Once upon a time in 1976, when bell-bottoms were in fashion and antibiotics ruled the world, Lyka Labs was born — a proud manufacturer of pharmaceutical formulations. Fast-forward to today, and it’s like watching a nostalgic sequel that’s still trying to find its audience.

Lyka Labs manufactures finished dosages and APIs across multiple therapeutic areas — dermatology, critical care, cosmeceuticals, and injectables. They’re WHO-GMP and ISO certified, so the quality’s legit. But profitability? Let’s just say the company’s bottom line could use a few steroid shots.

For FY25 and FY26, the company has been busy expanding its lyophilization capacity by 50% with a ₹290 million capex. It’s funded partly through debt and internal accruals — classic pharma juggle. On paper, the expansion looks promising, but the ₹36.66 crore Q2 sales and negative PAT of ₹3.22 crore make you wonder: are they manufacturing profits or just formulations?

Also, they’ve recently received patents for Pregabalin Gel 8% and regulatory permission for Tofacitinib Ointment 2% — big wins for R&D credibility. Yet, these haven’t translated into financial fireworks. The market clearly wants results that aren’t only dermatologically effective but financially curative.

3. Business Model – WTF Do They Even Do?

Alright, let’s decode this patient’s chart. Lyka Labs makes and markets pharmaceutical formulations and APIs. Think of them as a contract doctor for the big pharma houses — they take the raw material and packaging from clients, mix the magic, and ship out finished formulations.

Their specialities include lyophilized injections (fancy freeze-dried drugs), topical formulations (creams, gels, foams, lotions), and dermatological combinations. Essentially, if it can be applied, injected, or sold with a prescription, Lyka probably has a formulation for it.

Revenue split is crystal clear: Formulations account for ~92%, Bulk Drugs just ~3%, and the rest ~5% comes from miscellaneous income. Geographically, they’re well balanced — 53% exports and 47% domestic, spreading their risk better than most midcap pharma peers.

They also offer out-licensing and loan licensing services, basically renting out their formulations or facilities to other pharma firms. It’s like Airbnb for active pharmaceutical ingredients. And in FY22, they expanded into critical care (anti-infectives, oncology, antifungals) and animal healthcare — yes, Lyka’s curing both humans and animals now.

The business model is sound. The problem? The economics still look like a fresh MBBS intern’s bank account.

4. Financials Overview

Let’s dissect the Q2 FY26 results (Consolidated figures in ₹ crore):

Commentary:
That’s not a typo — Lyka swung from a ₹1.91 crore profit last year to a ₹3.22 crore loss this quarter. A pure 180° turn that would make even a chemist dizzy. QoQ, PAT fell off the cliff by over 400%. Meanwhile, the operating profit went negative, suggesting costs (especially material